Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Relapsed Small Cell Lung Cancer
NCT00052949Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2003
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoint: Proportion of patients progression-free at 16 weeks. Started May 2003; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00052949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052949.